首页 > 最新文献

中华心血管病杂志最新文献

英文 中文
[Remote home cardiac rehabilitation for a patient with left ventricular remodeling after old anterior myocardial infarction: a case report]. [陈旧性前壁心肌梗死后左心室重塑患者的远程家庭心脏康复治疗:病例报告]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20231013-00319
L Han, D Xu, R J Ding
{"title":"[Remote home cardiac rehabilitation for a patient with left ventricular remodeling after old anterior myocardial infarction: a case report].","authors":"L Han, D Xu, R J Ding","doi":"10.3760/cma.j.cn112148-20231013-00319","DOIUrl":"10.3760/cma.j.cn112148-20231013-00319","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1101-1103"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical practice guidelines for the management of hypertension in China]. [中国高血压管理临床实践指南]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20240709-00377
{"title":"[Clinical practice guidelines for the management of hypertension in China].","authors":"","doi":"10.3760/cma.j.cn112148-20240709-00377","DOIUrl":"10.3760/cma.j.cn112148-20240709-00377","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"985-1032"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intervention study on cardiovascular disease comorbid psychiatric and psychological problems]. [心血管疾病合并精神和心理问题干预研究]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20240515-00265
S Qu, D Y Hu
{"title":"[Intervention study on cardiovascular disease comorbid psychiatric and psychological problems].","authors":"S Qu, D Y Hu","doi":"10.3760/cma.j.cn112148-20240515-00265","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20240515-00265","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1110-1115"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Canagliflozin can improve cardiac function in HFpEF rats partly by regulating ferroptosis]. [卡那格列净可部分通过调节铁蛋白沉积来改善高密度脂蛋白血症大鼠的心脏功能]
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20240805-00439
S Ma, Q J Zuo, L L He, G R Zhang, J L Zhai, T T Zhang, Z L Wang, Y F Guo
<p><p><b>Objective:</b> To explore the effects of canagliflozin on cardiac function and its regulation of ferroptosis in rats with heart failure with preserved ejection fraction (HFpEF). <b>Methods:</b> Thirty-two 7-week-old Dahl salt-sensitive rats were selected and randomly divided into four groups: the control group (fed with low-salt diet), the HFpEF group (fed with high-salt diet), the canagliflozin 20 group (fed with high-salt diet and 20 mg·kg<sup>-1</sup>·d<sup>-1</sup> canagliflozin), and the canagliflozin 30 group (fed with high-salt diet and 30 mg·kg<sup>-1</sup>·day<sup>-1</sup> canagliflozin). Body weight and blood pressure of the rats in each group were monitored. Metabolic cage tests were conducted at the10<sup>th</sup> week of the experiment, and echocardiography was performed at the 12<sup>th</sup> week, after which the rats were killed. Blood and left ventricular samples were collected. HE staining, Masson staining, Prussian blue iron staining, and reactive oxygen species staining were performed to observe the cardiomyocyte size and shape, degree of interstitial fibrosis, iron staining, reactive oxygen species production under optical microscope. The ultrastructure of cardiomyocytes was observed under electron microscope. Western blotting and real-time fluorescent quantitative reverse transcription polymerase chain reaction (RT-qPCR) were used to detect the expression levels of proteins and mRNA related to ferroptosis in left ventricular myocardial tissue of rats in each group. <b>Results:</b> After 1 week of adaptive feeding, all rats survived. Metabolic cage results showed that compared with control group, rats in the HFpEF group, canagliflozin 20 group and canagliflozin 30 group had more food intake, water intake and urine output, and lower body weight (all <i>P</i><0.05). These changes were more pronounced in canagliflozin 20 group and canagliflozin 30 group than in HFPEF group, and only the body weight at the 12<sup>th</sup> week showed a statistically significant difference between canagliflozin 20 group and canagliflozin 30 group (<i>P</i><0.05). The blood pressure of 6<sup>th</sup> week and 12<sup>th</sup> week, heart weight and left ventricular corrected mass of 12<sup>th</sup> week of rats in HFpEF group were higher than those in control group, canagliflozin 20 group and canagliflozin 30 group, while the ratio of early mitral valve peak velocity to late mitral valve peak velocity of 12<sup>th</sup> week was lower (all <i>P</i><0.05). HE and Masson staining showed that compared to control group, the myocardial fibers in the left ventricular myocardial tissue of rats in HFpEF group were disordered, with larger cell diameter ((0.032±0.004) mm vs. (0.023±0.003) mm, <i>P</i><0.05), irregular shape, obvious proliferation of interstitial collagen fibers, and higher collagen volume fraction (0.168±0.028 vs. 0.118±0.013, <i>P</i><0.05). Compared with HFpEF group, rats in the canagliflozin 20 group and canagliflozin 30 had more
目的探讨卡格列净对射血分数保留型心力衰竭(HFpEF)大鼠心功能的影响及其对铁蛋白沉积的调节作用。研究方法选取32只7周大的Dahl盐敏感大鼠,随机分为四组:对照组(低盐饮食)、HFpEF组(高盐饮食)、卡那格列嗪20组(高盐饮食和20 mg-kg-1-d-1卡那格列嗪)和卡那格列嗪30组(高盐饮食和30 mg-kg-1-d-1卡那格列嗪)。监测各组大鼠的体重和血压。实验第 10 周进行代谢笼试验,第 12 周进行超声心动图检查,然后处死大鼠。收集血液和左心室样本。通过 HE 染色、Masson 染色、普鲁士蓝铁染色和活性氧染色,在光学显微镜下观察心肌细胞的大小和形状、间质纤维化程度、铁染色和活性氧生成情况。电镜下观察心肌细胞的超微结构。采用 Western 印迹和实时荧光定量反转录聚合酶链反应(RT-qPCR)检测各组大鼠左心室心肌组织中与铁沉积相关的蛋白质和 mRNA 的表达水平。结果适应性喂养 1 周后,所有大鼠均存活。代谢笼结果显示,与对照组相比,HFpEF组、canagliflozin 20组和canagliflozin 30组大鼠的进食量、进水量和尿量增加,体重降低(canagliflozin 20组和canagliflozin 30组大鼠第12周的体重差异均有统计学意义(第12周和第13周,HFpEF组大鼠第12周的心脏重量和左心室校正质量均高于对照组);canagliflozin 20组大鼠的进食量、进水量和尿量增加,体重降低(第12周和第13周,canagliflozin 20组和canagliflozin 30组大鼠的心脏重量和左心室校正质量均高于对照组)、第 12 周二尖瓣早期峰值速度与二尖瓣晚期峰值速度之比降低(所有 PPPP2+ 和心肌组织中丙二醛含量均高于对照组、canagliflozin 20 组和 canagliflozin 30 组,谷胱甘肽含量降低(所有 PPP>0.05).四组大鼠心肌组织中谷胱甘肽过氧化物酶 4 蛋白和 mRNA 表达水平无明显差异(P>0.05)。结论卡格列净可通过调节铁氧化机制改善高密度脂蛋白血症大鼠的心功能。
{"title":"[Canagliflozin can improve cardiac function in HFpEF rats partly by regulating ferroptosis].","authors":"S Ma, Q J Zuo, L L He, G R Zhang, J L Zhai, T T Zhang, Z L Wang, Y F Guo","doi":"10.3760/cma.j.cn112148-20240805-00439","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20240805-00439","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the effects of canagliflozin on cardiac function and its regulation of ferroptosis in rats with heart failure with preserved ejection fraction (HFpEF). &lt;b&gt;Methods:&lt;/b&gt; Thirty-two 7-week-old Dahl salt-sensitive rats were selected and randomly divided into four groups: the control group (fed with low-salt diet), the HFpEF group (fed with high-salt diet), the canagliflozin 20 group (fed with high-salt diet and 20 mg·kg&lt;sup&gt;-1&lt;/sup&gt;·d&lt;sup&gt;-1&lt;/sup&gt; canagliflozin), and the canagliflozin 30 group (fed with high-salt diet and 30 mg·kg&lt;sup&gt;-1&lt;/sup&gt;·day&lt;sup&gt;-1&lt;/sup&gt; canagliflozin). Body weight and blood pressure of the rats in each group were monitored. Metabolic cage tests were conducted at the10&lt;sup&gt;th&lt;/sup&gt; week of the experiment, and echocardiography was performed at the 12&lt;sup&gt;th&lt;/sup&gt; week, after which the rats were killed. Blood and left ventricular samples were collected. HE staining, Masson staining, Prussian blue iron staining, and reactive oxygen species staining were performed to observe the cardiomyocyte size and shape, degree of interstitial fibrosis, iron staining, reactive oxygen species production under optical microscope. The ultrastructure of cardiomyocytes was observed under electron microscope. Western blotting and real-time fluorescent quantitative reverse transcription polymerase chain reaction (RT-qPCR) were used to detect the expression levels of proteins and mRNA related to ferroptosis in left ventricular myocardial tissue of rats in each group. &lt;b&gt;Results:&lt;/b&gt; After 1 week of adaptive feeding, all rats survived. Metabolic cage results showed that compared with control group, rats in the HFpEF group, canagliflozin 20 group and canagliflozin 30 group had more food intake, water intake and urine output, and lower body weight (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). These changes were more pronounced in canagliflozin 20 group and canagliflozin 30 group than in HFPEF group, and only the body weight at the 12&lt;sup&gt;th&lt;/sup&gt; week showed a statistically significant difference between canagliflozin 20 group and canagliflozin 30 group (&lt;i&gt;P&lt;/i&gt;&lt;0.05). The blood pressure of 6&lt;sup&gt;th&lt;/sup&gt; week and 12&lt;sup&gt;th&lt;/sup&gt; week, heart weight and left ventricular corrected mass of 12&lt;sup&gt;th&lt;/sup&gt; week of rats in HFpEF group were higher than those in control group, canagliflozin 20 group and canagliflozin 30 group, while the ratio of early mitral valve peak velocity to late mitral valve peak velocity of 12&lt;sup&gt;th&lt;/sup&gt; week was lower (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). HE and Masson staining showed that compared to control group, the myocardial fibers in the left ventricular myocardial tissue of rats in HFpEF group were disordered, with larger cell diameter ((0.032±0.004) mm vs. (0.023±0.003) mm, &lt;i&gt;P&lt;/i&gt;&lt;0.05), irregular shape, obvious proliferation of interstitial collagen fibers, and higher collagen volume fraction (0.168±0.028 vs. 0.118±0.013, &lt;i&gt;P&lt;/i&gt;&lt;0.05). Compared with HFpEF group, rats in the canagliflozin 20 group and canagliflozin 30 had more ","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1090-1100"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[BAG3 gene related restrictive cardiomyopathy: a case report]. [与 BAG3 基因相关的限制性心肌病:一份病例报告]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20231123-00458
P Y Zhou, S H Zhao
{"title":"[BAG3 gene related restrictive cardiomyopathy: a case report].","authors":"P Y Zhou, S H Zhao","doi":"10.3760/cma.j.cn112148-20231123-00458","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20231123-00458","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1104-1106"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Relationship between cardiopulmonary exercise testing and the prognosis of cardiovascular disease in coronary heart disease patients]. [冠心病患者心肺运动测试与心血管疾病预后的关系]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20231007-00218
Y S Li, J Zhang, Q Ren, Y C Liang, Q Y Zhang, Y L Han

Objective: To investigate the predictive value of cardiopulmonary exercise test (CPET) indexes for major adverse cardiovascular events (MACE) in patients with coronary heart disease (CHD). Methods: This study was a retrospective cohort study. CHD patients were consecutively enrolled who procedure CPET before discharge from the Department of Cardiology, General Hospital of Northern Theater Command from November 2015 to September 2021 were enrolled. Demographic information, past medical history, CPET indexes and other baseline data were collected and the patients were followed up. Patients were divided into a MACE group and a control group according to the presence or absence of MACE. A multivariate Cox proportional hazard regression model was used to analyze the CPET indexes with predictive value for MACE in CHD patients. Results: A total of 3 800 patients were eligible for the criterion, age (57.2±8.8) years, 2 920 (76.84%) males. During a follow-up of 1 237 (695, 1 596) days, 390 (10.26%) patients were in MACE group, and 3 410 (89.74%) patients were in control group. In adjusted multivariable analysis, higher metabolic equivalent of tasks (MET) at anaerobic threshold (AT) is an independent protective factor for MACE in patients with CHD (HR=0.75, 95%CI 0.62-0.90, P=0.002), higher VE/VCO2 is an independent risk factor for MACE in CHD patients (HR=1.05, 95%CI 1.02-1.07, P=0.001). Conclusion: In CPET, high MET at AT is an independent protective factor for MACE in patients with CHD, and high VE/VCO2 is an independent risk factor for MACE in CHD patients.

目的研究心肺运动测试(CPET)指标对冠心病(CHD)患者主要不良心血管事件(MACE)的预测价值。研究方法本研究是一项回顾性队列研究。研究连续纳入了2015年11月至2021年9月在北部战区司令部总医院心内科出院前进行CPET的冠心病患者。收集了人口统计学信息、既往病史、CPET指标和其他基线数据,并对患者进行了随访。根据有无MACE将患者分为MACE组和对照组。采用多变量考克斯比例危险回归模型分析对冠心病患者 MACE 有预测价值的 CPET 指标。研究结果符合标准的患者共有 3 800 人,年龄(57.2±8.8)岁,男性 2 920 人(76.84%)。在1 237(695,1 596)天的随访中,390(10.26%)名患者属于MACE组,3 410(89.74%)名患者属于对照组。在调整后的多变量分析中,无氧阈值(AT)下较高的代谢当量(MET)是冠心病患者发生 MACE 的独立保护因素(HR=0.75,95%CI 0.62-0.90,P=0.002),较高的 VE/VCO2 是冠心病患者发生 MACE 的独立风险因素(HR=1.05,95%CI 1.02-1.07,P=0.001)。结论在 CPET 中,AT 时的高 MET 是冠心病患者发生 MACE 的独立保护因素,而高 VE/VCO2 是冠心病患者发生 MACE 的独立危险因素。
{"title":"[Relationship between cardiopulmonary exercise testing and the prognosis of cardiovascular disease in coronary heart disease patients].","authors":"Y S Li, J Zhang, Q Ren, Y C Liang, Q Y Zhang, Y L Han","doi":"10.3760/cma.j.cn112148-20231007-00218","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20231007-00218","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the predictive value of cardiopulmonary exercise test (CPET) indexes for major adverse cardiovascular events (MACE) in patients with coronary heart disease (CHD). <b>Methods:</b> This study was a retrospective cohort study. CHD patients were consecutively enrolled who procedure CPET before discharge from the Department of Cardiology, General Hospital of Northern Theater Command from November 2015 to September 2021 were enrolled. Demographic information, past medical history, CPET indexes and other baseline data were collected and the patients were followed up. Patients were divided into a MACE group and a control group according to the presence or absence of MACE. A multivariate Cox proportional hazard regression model was used to analyze the CPET indexes with predictive value for MACE in CHD patients. <b>Results:</b> A total of 3 800 patients were eligible for the criterion, age (57.2±8.8) years, 2 920 (76.84%) males. During a follow-up of 1 237 (695, 1 596) days, 390 (10.26%) patients were in MACE group, and 3 410 (89.74%) patients were in control group. In adjusted multivariable analysis, higher metabolic equivalent of tasks (MET) at anaerobic threshold (AT) is an independent protective factor for MACE in patients with CHD (<i>HR</i>=0.75, 95%<i>CI</i> 0.62-0.90, <i>P</i>=0.002), higher VE/VCO<sub>2</sub> is an independent risk factor for MACE in CHD patients (<i>HR</i>=1.05, 95%<i>CI</i> 1.02-1.07, <i>P</i>=0.001). <b>Conclusion:</b> In CPET, high MET at AT is an independent protective factor for MACE in patients with CHD, and high VE/VCO<sub>2</sub> is an independent risk factor for MACE in CHD patients.</p>","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1044-1050"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research advances on the role of histone modification in cardiac aging and related vascular diseases]. [组蛋白修饰在心脏衰老和相关血管疾病中作用的研究进展]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20231008-00253
J J Wang, Y F Huang, J Zhang, J Yang
{"title":"[Research advances on the role of histone modification in cardiac aging and related vascular diseases].","authors":"J J Wang, Y F Huang, J Zhang, J Yang","doi":"10.3760/cma.j.cn112148-20231008-00253","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20231008-00253","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1126-1130"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Keeping abreast of the times, the Chinese guidelines for the diagnosis and management of chronic coronary syndrome]. [与时俱进,中国慢性冠脉综合征诊治指南]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20240611-00325
P M Liu, Y L Han
{"title":"[Keeping abreast of the times, the Chinese guidelines for the diagnosis and management of chronic coronary syndrome].","authors":"P M Liu, Y L Han","doi":"10.3760/cma.j.cn112148-20240611-00325","DOIUrl":"https://doi.org/10.3760/cma.j.cn112148-20240611-00325","url":null,"abstract":"","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"976-979"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intervention of traditional Chinese patent medicine based on syndrome differentiation in female patients after percutaneous coronary intervention due to acute coronary syndrome: a nationwide multicenter prospective cohort study]. [急性冠状动脉综合征经皮冠状动脉介入治疗后女性患者的分型中成药干预:全国多中心前瞻性队列研究]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20231023-00372
R N Bai, F Gu, Y J Cai, S Sheng, Q N Yang, R X Xi, L Z Li, D Z Shi
<p><p><b>Objective:</b> To evaluate the efficacy and safety of discriminative application of Chinese patent medicines in female patients after percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS). <b>Methods:</b> The study population was from the Chinese Patent Medicine (CPM) trial. CPM trial was a multicenter prospective cohort study, which enrolled patients from 40 centers in mainland China between February 2012 and December 2015, with the discriminative use of Chinese patent medicines as the exposure factor. Female patients with ACS after PCI who completed 36-month follow-up were included in this analysis, and were divided into a conventional treatment group (using conventional western medicine recommended by the guidelines) and a group with the discriminative use of proprietary Chinese medicines (on the basis of conventional western medicine treatment, discriminative use of Qishen Yiqi dropping pills for Qi deficiency and blood stasis syndrome, Guanxin Danshen dropping pills for blood stasis syndrome, and Danlou tablets for phlegm and blood stasis syndrome combined with the conventional western medicine). The primary endpoint event was a composite endpoint event including cardiovascular death, nonfatal myocardial infarction, and emergency revascularization surgery. Secondary endpoint events were composite endpoint events including readmission for ACS, heart failure, stroke, and other thrombotic events. Adverse events were collected. Cox proportional risk model was used to assess the effect of discriminatory application of Chinese patent medicine on endpoint events, and sensitivity analysis was performed by comparing the results with propensity score matching analysis. <b>Results:</b> A total of 748 female ACS post-PCI patients were included in the analysis, aged (63.2±8.3) years. There were 370 patients in the group of discriminative application of Chinese patent medicines and 378 patients in the conventional treatment group. There were 37 cases (10.0%) and 58 cases (15.3%) of primary endpoint events in the discriminatory application of Chinese patent medicines group and the conventional treatment group, respectively. Cox analysis showed that the risk of primary endpoint in the discriminatory application of Chinese patent medicines group was lower than that in the conventional treatment group after adjusting for confounding factors (adjusted <i>HR</i>=0.62, 95%<i>CI</i> 0.40-0.96, <i>P</i>=0.031). There were 38 (10.3%) and 57 (15.1%) cases of secondary endpoint events in the two groups, respectively. Cox regression analysis showed that the risk of secondary endpoint events in the discriminatory application of Chinese patent medicine group was lower than that in the conventional treatment group after adjusting for confounders (adjusted <i>HR</i>=0.56, 95%<i>CI</i> 0.37-0.87, <i>P</i>=0.001). The results of propensity score matching analysis also showed that Chinese patent medicines based on discriminatory application c
目的评估急性冠状动脉综合征(ACS)经皮冠状动脉介入治疗(PCI)后女性患者辨证应用中成药的疗效和安全性。方法研究人群来自中成药(CPM)试验。CPM试验是一项多中心前瞻性队列研究,于2012年2月至2015年12月期间在中国大陆的40个中心招募患者,以中成药的辨证使用作为暴露因素。本次分析纳入了完成36个月随访的PCI术后ACS女性患者,并将其分为常规治疗组(采用指南推荐的常规西药治疗)和中成药辨证施治组(在常规西药治疗的基础上,辨证使用治疗气虚血瘀证的芪参益气滴丸、治疗血瘀证的冠心丹参滴丸、治疗痰瘀证的丹络片,并结合常规西药治疗)。主要终点事件为复合终点事件,包括心血管死亡、非致死性心肌梗死和急诊血管重建手术。次要终点事件为复合终点事件,包括因急性心肌梗死、心力衰竭、中风和其他血栓事件再入院。收集了不良事件。采用Cox比例风险模型评估中成药辨证应用对终点事件的影响,并通过比较倾向得分匹配分析结果进行敏感性分析。结果共有 748 例女性 ACS PCI 后患者纳入分析,年龄为(63.2±8.3)岁。中成药辨证施治组 370 例,常规治疗组 378 例。辨证应用中成药组和常规治疗组分别有 37 例(10.0%)和 58 例(15.3%)发生主要终点事件。Cox分析显示,调整混杂因素后,辨证应用中成药组的主要终点风险低于常规治疗组(调整后HR=0.62,95%CI 0.40-0.96,P=0.031)。两组分别有38例(10.3%)和57例(15.1%)发生次要终点事件。Cox回归分析显示,调整混杂因素后,辨证应用中成药组发生次要终点事件的风险低于常规治疗组(调整后HR=0.56,95%CI 0.37-0.87,P=0.001)。倾向得分匹配分析结果也显示,基于辨证施治的中成药可显著降低主要终点(HR=0.62,95%CI 0.40-0.97,P=0.033)和次要终点(HR=0.56,95%CI 0.37-0.87,P=0.009)的风险。两组患者的不良反应无明显差异(12.4% (46/370) vs. 10.3% (39/378),P=0.362)。结论在常规西医治疗的基础上,辨证应用中成药可降低因 ACS 而行 PCI 术后女性患者的终点风险,且无明显不良反应。
{"title":"[Intervention of traditional Chinese patent medicine based on syndrome differentiation in female patients after percutaneous coronary intervention due to acute coronary syndrome: a nationwide multicenter prospective cohort study].","authors":"R N Bai, F Gu, Y J Cai, S Sheng, Q N Yang, R X Xi, L Z Li, D Z Shi","doi":"10.3760/cma.j.cn112148-20231023-00372","DOIUrl":"10.3760/cma.j.cn112148-20231023-00372","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the efficacy and safety of discriminative application of Chinese patent medicines in female patients after percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS). &lt;b&gt;Methods:&lt;/b&gt; The study population was from the Chinese Patent Medicine (CPM) trial. CPM trial was a multicenter prospective cohort study, which enrolled patients from 40 centers in mainland China between February 2012 and December 2015, with the discriminative use of Chinese patent medicines as the exposure factor. Female patients with ACS after PCI who completed 36-month follow-up were included in this analysis, and were divided into a conventional treatment group (using conventional western medicine recommended by the guidelines) and a group with the discriminative use of proprietary Chinese medicines (on the basis of conventional western medicine treatment, discriminative use of Qishen Yiqi dropping pills for Qi deficiency and blood stasis syndrome, Guanxin Danshen dropping pills for blood stasis syndrome, and Danlou tablets for phlegm and blood stasis syndrome combined with the conventional western medicine). The primary endpoint event was a composite endpoint event including cardiovascular death, nonfatal myocardial infarction, and emergency revascularization surgery. Secondary endpoint events were composite endpoint events including readmission for ACS, heart failure, stroke, and other thrombotic events. Adverse events were collected. Cox proportional risk model was used to assess the effect of discriminatory application of Chinese patent medicine on endpoint events, and sensitivity analysis was performed by comparing the results with propensity score matching analysis. &lt;b&gt;Results:&lt;/b&gt; A total of 748 female ACS post-PCI patients were included in the analysis, aged (63.2±8.3) years. There were 370 patients in the group of discriminative application of Chinese patent medicines and 378 patients in the conventional treatment group. There were 37 cases (10.0%) and 58 cases (15.3%) of primary endpoint events in the discriminatory application of Chinese patent medicines group and the conventional treatment group, respectively. Cox analysis showed that the risk of primary endpoint in the discriminatory application of Chinese patent medicines group was lower than that in the conventional treatment group after adjusting for confounding factors (adjusted &lt;i&gt;HR&lt;/i&gt;=0.62, 95%&lt;i&gt;CI&lt;/i&gt; 0.40-0.96, &lt;i&gt;P&lt;/i&gt;=0.031). There were 38 (10.3%) and 57 (15.1%) cases of secondary endpoint events in the two groups, respectively. Cox regression analysis showed that the risk of secondary endpoint events in the discriminatory application of Chinese patent medicine group was lower than that in the conventional treatment group after adjusting for confounders (adjusted &lt;i&gt;HR&lt;/i&gt;=0.56, 95%&lt;i&gt;CI&lt;/i&gt; 0.37-0.87, &lt;i&gt;P&lt;/i&gt;=0.001). The results of propensity score matching analysis also showed that Chinese patent medicines based on discriminatory application c","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1073-1080"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A clinical randomized controlled study on the psycho-cardiological therapy for patients with coronary atherosclerosis disease]. [冠状动脉粥样硬化症患者的心血管心理治疗临床随机对照研究]。
Q3 Medicine Pub Date : 2024-09-24 DOI: 10.3760/cma.j.cn112148-20240528-00293
L J Zhang, Y P Chi, D F He, G Li, N Lu, Y W Li, S Wang, M Y Liu

Objective: To explore the prognosis efficacy of psycho-cardiological therapy and management on patients with coronary atherosclerosis disease (CAD). Methods: This was a clinical randomized controlled study. This study included inpatients with CAD at the cardiology department in Beijing Anzhen Hospital, Capital Medical University from August 2021 to January 2024. The patients enrolled in this study were asked for basic information, and received measurements for depression, anxiety, sleep quality and living quality by the scales of Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder scale-7 (GAD-7), Athens Insomnia Scale (AIS), EuroQol 5-dimension 5-level (EQ-5D-5L) respectively. The patients were randomly grouped into a regular treatment group and a psycho-cardiological treatment group which included WeChat management or antidepressant/antianxiety medical therapy according to the situation. After the patients discharging from hospital for 2, 4, 12, 24, 48, 72, and 96 weeks, professional cardiovascular doctors would follow up by telephone, WeChat, and outpatient department, including scales (2-48 weeks), and cardiac events (2-96 weeks). Kaplan-Meier survival curve and multivariate Cox proportional hazards model were used for analyzing the association between psycho-cardiological treatment and cardiac events. Results: This study recruited a total of 552 patients with CAD, aged 61.0(54.0, 67.0) years, and 379 (68.7%) were male. There were 279(50.5%) in the regular treatment group and 273(49.5%) in the psycho-cardiological treatment group. After treatment for 4, 12 and 48 weeks, the PHQ-9 score in psycho-cardiological was significantly lower than the regular treatment group; After treatment for 12 weeks, the EQ-5D-5L effective value in psycho-cardiological group was higher than the regular treatment group; After treatment for 2, 4, 12, 24 and 48 weeks, the EQ-5D-5L VAS score in psycho-cardiological group was higher than the regular therapy group (all P<0.05). The Kaplan-Meier survival curve showed that, during the different follow-up periods, the rate of cardiac events in psycho-cardiological treatment group was lower than regular treatment group (log-rank P<0.001). The multivariate Cox proportional hazards model adjusted the factor of age, the psycho-cardiological treatment contributed to reducing the cardiac events rate by 80.3% (HR=0.197, 95%CI: 0.067-0.582, P=0.003). Conclusion: Psycho-cardiological treatment is beneficial for improving psychological stress, living quality, and reducing cardiac events, and helps to improve prognosis and psycho-cardiological rehabilitation in CAD patients.

目的探讨冠状动脉粥样硬化症(CAD)患者的心血管心理治疗和管理的预后效果。方法:这是一项临床随机对照研究:这是一项临床随机对照研究。研究对象为 2021 年 8 月至 2024 年 1 月在首都医科大学附属北京安贞医院心内科住院的冠状动脉粥样硬化患者。研究人员询问了患者的基本信息,并通过患者健康问卷-9(PHQ-9)、一般焦虑症量表-7(GAD-7)、雅典失眠量表(AIS)、EQ-5D-5L(EuroQol 5-dimension 5-level)等量表分别测量了患者的抑郁、焦虑、睡眠质量和生活质量。根据情况将患者随机分为常规治疗组和心身医学治疗组,后者包括微信管理或抗抑郁/焦虑药物治疗。患者出院2、4、12、24、48、72、96周后,由专业心血管医生通过电话、微信、门诊等方式进行随访,包括量表(2-48周)、心脏事件(2-96周)等。采用Kaplan-Meier生存曲线和多变量Cox比例危险模型分析心血管心理治疗与心脏事件之间的关系。研究结果本研究共招募了 552 例 CAD 患者,年龄为 61.0(54.0,67.0)岁,其中男性 379 例(68.7%)。常规治疗组有 279 人(50.5%),心血管心理治疗组有 273 人(49.5%)。治疗4周、12周和48周后,心身医学组的PHQ-9评分明显低于常规治疗组;治疗12周后,心身医学组的EQ-5D-5L有效值高于常规治疗组;治疗2周、4周、12周、24周和48周后,心身医学组的EQ-5D-5L VAS评分高于常规治疗组(所有PPHR=0.197,95%CI:0.067-0.582,P=0.003)。结论心血管心理治疗有利于改善CAD患者的心理压力、生活质量和减少心脏事件,有助于改善CAD患者的预后和心血管心理康复。
{"title":"[A clinical randomized controlled study on the psycho-cardiological therapy for patients with coronary atherosclerosis disease].","authors":"L J Zhang, Y P Chi, D F He, G Li, N Lu, Y W Li, S Wang, M Y Liu","doi":"10.3760/cma.j.cn112148-20240528-00293","DOIUrl":"10.3760/cma.j.cn112148-20240528-00293","url":null,"abstract":"<p><p><b>Objective:</b> To explore the prognosis efficacy of psycho-cardiological therapy and management on patients with coronary atherosclerosis disease (CAD). <b>Methods:</b> This was a clinical randomized controlled study. This study included inpatients with CAD at the cardiology department in Beijing Anzhen Hospital, Capital Medical University from August 2021 to January 2024. The patients enrolled in this study were asked for basic information, and received measurements for depression, anxiety, sleep quality and living quality by the scales of Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder scale-7 (GAD-7), Athens Insomnia Scale (AIS), EuroQol 5-dimension 5-level (EQ-5D-5L) respectively. The patients were randomly grouped into a regular treatment group and a psycho-cardiological treatment group which included WeChat management or antidepressant/antianxiety medical therapy according to the situation. After the patients discharging from hospital for 2, 4, 12, 24, 48, 72, and 96 weeks, professional cardiovascular doctors would follow up by telephone, WeChat, and outpatient department, including scales (2-48 weeks), and cardiac events (2-96 weeks). Kaplan-Meier survival curve and multivariate Cox proportional hazards model were used for analyzing the association between psycho-cardiological treatment and cardiac events. <b>Results:</b> This study recruited a total of 552 patients with CAD, aged 61.0(54.0, 67.0) years, and 379 (68.7%) were male. There were 279(50.5%) in the regular treatment group and 273(49.5%) in the psycho-cardiological treatment group. After treatment for 4, 12 and 48 weeks, the PHQ-9 score in psycho-cardiological was significantly lower than the regular treatment group; After treatment for 12 weeks, the EQ-5D-5L effective value in psycho-cardiological group was higher than the regular treatment group; After treatment for 2, 4, 12, 24 and 48 weeks, the EQ-5D-5L VAS score in psycho-cardiological group was higher than the regular therapy group (all <i>P</i><0.05). The Kaplan-Meier survival curve showed that, during the different follow-up periods, the rate of cardiac events in psycho-cardiological treatment group was lower than regular treatment group (log-rank <i>P</i><0.001). The multivariate Cox proportional hazards model adjusted the factor of age, the psycho-cardiological treatment contributed to reducing the cardiac events rate by 80.3% (<i>HR</i>=0.197, 95%<i>CI</i>: 0.067-0.582, <i>P</i>=0.003). <b>Conclusion:</b> Psycho-cardiological treatment is beneficial for improving psychological stress, living quality, and reducing cardiac events, and helps to improve prognosis and psycho-cardiological rehabilitation in CAD patients.</p>","PeriodicalId":38755,"journal":{"name":"中华心血管病杂志","volume":"52 9","pages":"1051-1057"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华心血管病杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1